BiotechTube

PGN-EDODM1 for infusion

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy 1

Conditions

Myotonic Dystrophy 1

Trial Timeline

Dec 12, 2023 → Oct 28, 2025

NCT ID
NCT06204809

About PGN-EDODM1 for infusion

PGN-EDODM1 for infusion is a phase 1 stage product being developed by PepGen for Myotonic Dystrophy 1. The current trial status is completed. This product is registered under clinical trial identifier NCT06204809. Target conditions include Myotonic Dystrophy 1.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06204809Phase 1Completed

Competing Products

16 competing products in Myotonic Dystrophy 1

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
15
TideglusibAMO PharmaPhase 2
44
Tideglusib + PlaceboAMO PharmaPhase 2/3
57
TideglusibAMO PharmaPhase 2/3
57
VX-670Vertex PharmaceuticalsPhase 2
51
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
40
SAR446268SanofiPhase 1/2
40
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
49
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
38
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
74
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
38
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
72
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
36
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
47
PGN-EDODM1PepGenPhase 2
44
PGN-EDODM1PepGenPhase 2
44

Other Products from PepGen

PGN-EDODM1Phase 2
44
PGN-EDODM1Phase 2
44
IV infusionPhase 2
44
PGN-EDO51Phase 2
44